Ataru Sazawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ataru Sazawa has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Nobuo Shinohara
Department of Renal and Genitourinary Surgery Hokkaido University Graduate School of Medicine Sapporo Japan
7 shared publications Katsuya Nonomura
5 shared publicationsTakashige Abe
4 shared publications- Satoru Maruyama
Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
3 shared publications Hisakazu Fujita
Division of Cancer Gene Regulation, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
2 shared publicationsKazunori Haga
Division of Cancer Gene Regulation, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
2 shared publications
Latest Publications
- 1 January 2013
- Vol. 10 (1) , 784-9
Long-term renal function outcomes in bladder cancer after radical cystectomy.
To evaluate postoperative renal function and risk factors for the loss of renal function in patients who had undergone radical cystectomy. A retrospective single institutional study evaluated 70 patients, including 54 men and 16 women who underwent radical cystectomy. The median follow-up period was 34.5 months (range, 12 to 228 months). In this cohort, four types of urinary diversions were studied, including ileal neobladder (n = 24), ileocecal neobladder (n = 12), ileal conduit (n = 25), and cutaneous ureterostomy (n = 9). Postoperative changes in renal function were reviewed, and the estimated serum creatinine-based glomerular filtration rate (eGFR) was calculated. The variables analyzed were age, a prior history of hypertension or diabetes mellitus, pre-operative renal function, type of urinary diversion, the postoperative occurrence of acute pyelonephritis, and the presence of chemotherapy. The mean eGFR was 74.6 (range, 15.2 to 155.1) mL/min/1.73 m² before surgery and 63.6 (range, 8.7 to 111.5) mL/min/1.73 m² at the last follow-up. The 10-year renal deterioration-free interval was 63.8%. Multivariate analysis showed that a postoperative episode of acute pyelonephritis [Odds Ratio (OR), 3.21; 95% Confidence Interval (CI), 1.14 to 9.02; P = .03] and the presence of chemotherapy (OR, 3.27; 95% CI, 1.33 to 8.01; P = .01) were significant adverse factors. Twenty-four (34.2%) patients demonstrated reduced renal function during the follow-up period. Postoperative episodes of acute pyelonephritis and the presence of chemotherapy were found to be significant adverse factors.
- 1 January 2013
- Vol. 10 (1) , 784-9
Long-term renal function outcomes in bladder cancer after radical cystectomy.
To evaluate postoperative renal function and risk factors for the loss of renal function in patients who had undergone radical cystectomy. A retrospective single institutional study evaluated 70 patients, including 54 men and 16 women who underwent radical cystectomy. The median follow-up period was 34.5 months (range, 12 to 228 months). In this cohort, four types of urinary diversions were studied, including ileal neobladder (n = 24), ileocecal neobladder (n = 12), ileal conduit (n = 25), and cutaneous ureterostomy (n = 9). Postoperative changes in renal function were reviewed, and the estimated serum creatinine-based glomerular filtration rate (eGFR) was calculated. The variables analyzed were age, a prior history of hypertension or diabetes mellitus, pre-operative renal function, type of urinary diversion, the postoperative occurrence of acute pyelonephritis, and the presence of chemotherapy. The mean eGFR was 74.6 (range, 15.2 to 155.1) mL/min/1.73 m² before surgery and 63.6 (range, 8.7 to 111.5) mL/min/1.73 m² at the last follow-up. The 10-year renal deterioration-free interval was 63.8%. Multivariate analysis showed that a postoperative episode of acute pyelonephritis [Odds Ratio (OR), 3.21; 95% Confidence Interval (CI), 1.14 to 9.02; P = .03] and the presence of chemotherapy (OR, 3.27; 95% CI, 1.33 to 8.01; P = .01) were significant adverse factors. Twenty-four (34.2%) patients demonstrated reduced renal function during the follow-up period. Postoperative episodes of acute pyelonephritis and the presence of chemotherapy were found to be significant adverse factors.
- 10 February 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (5) , 400
Prognosis of patients with renal cell carcinoma with disease recurrence following nephrectomy for localized disease.
400 Background: We investigated the prognosis of Japanese patients with recurrent renal cell carcinoma (RCC) following nephrectomy, and analyzed the prognostic impact of metastasectomy and Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification in these patients. Methods: Between 1995 and 2005, 214 patients with recurrent RCC were the subjects of this retrospective analysis. At recurrence, MSKCC risk classification was used to classify patients as being at favorable, intermediate, and poor risk. The endpoint of the present study was overall survival (OS) from time of recurrence. Relationships between overall survival and potential prognostic factors were assessed using the Cox proportional hazard model. Results: Median time to recurrence following nephrectomy was 25 months. At recurrence, 148 (69%) patients had metastasis in one organ and lung was the most common site of recurrence (123 pts, 57%). The median survival from the time of recurrence was 40 months; the estimated 2-year survival rate was 66% (95% CI 60-73). When the MSKCC risk classification was applied to the patients, the median overall survival was not reached, 29 months, and 11 months in the patients classified as favorable (59 pts), intermediate (101 pts), and poor risk (24 pts), respectively. Metastasectomy was performed in 76 (36%) patients. The median survival from the time of recurrence in these patients was 122 months, which was significantly longer than the median survival (27 months) of patients who did not undergo metastasectomy (p Conclusions: In patients with recurrent RCC following nephrectomy for localized disease, patients classified as favorable risk according to MSKCC risk classification have a good opportunity for long-term survival, especially those who undergo metastasectomy.
- 10 February 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (5) , 400
Prognosis of patients with renal cell carcinoma with disease recurrence following nephrectomy for localized disease.
400 Background: We investigated the prognosis of Japanese patients with recurrent renal cell carcinoma (RCC) following nephrectomy, and analyzed the prognostic impact of metastasectomy and Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification in these patients. Methods: Between 1995 and 2005, 214 patients with recurrent RCC were the subjects of this retrospective analysis. At recurrence, MSKCC risk classification was used to classify patients as being at favorable, intermediate, and poor risk. The endpoint of the present study was overall survival (OS) from time of recurrence. Relationships between overall survival and potential prognostic factors were assessed using the Cox proportional hazard model. Results: Median time to recurrence following nephrectomy was 25 months. At recurrence, 148 (69%) patients had metastasis in one organ and lung was the most common site of recurrence (123 pts, 57%). The median survival from the time of recurrence was 40 months; the estimated 2-year survival rate was 66% (95% CI 60-73). When the MSKCC risk classification was applied to the patients, the median overall survival was not reached, 29 months, and 11 months in the patients classified as favorable (59 pts), intermediate (101 pts), and poor risk (24 pts), respectively. Metastasectomy was performed in 76 (36%) patients. The median survival from the time of recurrence in these patients was 122 months, which was significantly longer than the median survival (27 months) of patients who did not undergo metastasectomy (p Conclusions: In patients with recurrent RCC following nephrectomy for localized disease, patients classified as favorable risk according to MSKCC risk classification have a good opportunity for long-term survival, especially those who undergo metastasectomy.
- 10 February 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (5) , 65
Can PSA doubling time exactly predict the candidates for active surveillance in patients with low-risk prostate cancer?
65 Background: Currently, there are few well-validated data of PSA kinetics (PSA doubling time [PSADT] and PSA velocity) in active surveillance protocols. The objective of the study was to elucidate whether PSADT could predict patients with low-risk prostate cancer suitable for active surveillance (AS). Methods: The study included 149 consecutive patients treated with radical prostatectomy (RP). We selected patients who could be candidates for AS (PSA≤10ng/ml and Gleason score (GS)≤3+3 and cT1-2N0M0). PSA had been measured two times at least in a year before surgery. After all, from April 2000 to March 2008, we retrospectively reviewed a total of 47 patients (median age were 64 years, range: 53-75). Patients were divided into the following two groups: patients whose PSADT Results: In the whole specimen of 47 pts, upgraded to Gleason score 7-8, extracapsular extension (ECE: pT3a disease), seminal vesicle involvement and upstaged were 23 (49%), 7 (15%), none (0%) and 7 (15%), respectively. No statistical significance was observed in occurrence rates of upgrading and upstaging between Rapid group (56%, 19%) and Non-rapid group (45%, 13%). There was no significant difference in biochemical-free survival rates in two groups (5-year bRFS were 71% and 77%, respectively). The Cox proportional hazards analysis demonstrated that any pre-operative factors including PSADT were not significant risk factors for biochemical relapse. Conclusions: Our findings revealed that pre-opeative PSADT did not reliably predict pathology and prognosis after RP in those who were candidates for AS. PSADT is not suitable for selection criteria and for monitoring on active surveillance.
- 10 February 2012
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (5) , 65
Can PSA doubling time exactly predict the candidates for active surveillance in patients with low-risk prostate cancer?
65 Background: Currently, there are few well-validated data of PSA kinetics (PSA doubling time [PSADT] and PSA velocity) in active surveillance protocols. The objective of the study was to elucidate whether PSADT could predict patients with low-risk prostate cancer suitable for active surveillance (AS). Methods: The study included 149 consecutive patients treated with radical prostatectomy (RP). We selected patients who could be candidates for AS (PSA≤10ng/ml and Gleason score (GS)≤3+3 and cT1-2N0M0). PSA had been measured two times at least in a year before surgery. After all, from April 2000 to March 2008, we retrospectively reviewed a total of 47 patients (median age were 64 years, range: 53-75). Patients were divided into the following two groups: patients whose PSADT Results: In the whole specimen of 47 pts, upgraded to Gleason score 7-8, extracapsular extension (ECE: pT3a disease), seminal vesicle involvement and upstaged were 23 (49%), 7 (15%), none (0%) and 7 (15%), respectively. No statistical significance was observed in occurrence rates of upgrading and upstaging between Rapid group (56%, 19%) and Non-rapid group (45%, 13%). There was no significant difference in biochemical-free survival rates in two groups (5-year bRFS were 71% and 77%, respectively). The Cox proportional hazards analysis demonstrated that any pre-operative factors including PSADT were not significant risk factors for biochemical relapse. Conclusions: Our findings revealed that pre-opeative PSADT did not reliably predict pathology and prognosis after RP in those who were candidates for AS. PSADT is not suitable for selection criteria and for monitoring on active surveillance.
- 8 April 2009
- Published by Wiley in International Journal of Urology
- Vol. 16 (4) , 410-412
Alternative approach in the treatment of adrenal metastasis with a real-time tracking radiotherapy in patients with hormone refractory prostate cancer
Patients with an adrenal tumor usually undergo laparoscopic adrenalectomy. However, an alternative treatment approach might be needed in some patients with adrenal metastasis from malignancy or with severe complications. Real-time tracking radiotherapy (RTRT) with a gold marker is considered one of the feasible treatment options because this system can reduce the adverse effects of organ movement such as that in the adrenal gland or kidney. A 64-year-old patient with hormone refractory prostate cancer presented with clinically isolated adrenal metastasis. The patient underwent RTRT treatment with an implanted gold marker in the right adrenal metastasis. There were no adverse events. Although disease progression with elevated prostate-specific antigen occurred 8 months later, there was no further growth of the right adrenal metastasis before he died. From our experience, RTRT with an implanted gold marker might be feasible for the treatment of isolated adrenal metastasis from malignancies including prostate cancer.
- 8 April 2009
- Published by Wiley in International Journal of Urology
- Vol. 16 (4) , 410-412
Alternative approach in the treatment of adrenal metastasis with a real-time tracking radiotherapy in patients with hormone refractory prostate cancer
Patients with an adrenal tumor usually undergo laparoscopic adrenalectomy. However, an alternative treatment approach might be needed in some patients with adrenal metastasis from malignancy or with severe complications. Real-time tracking radiotherapy (RTRT) with a gold marker is considered one of the feasible treatment options because this system can reduce the adverse effects of organ movement such as that in the adrenal gland or kidney. A 64-year-old patient with hormone refractory prostate cancer presented with clinically isolated adrenal metastasis. The patient underwent RTRT treatment with an implanted gold marker in the right adrenal metastasis. There were no adverse events. Although disease progression with elevated prostate-specific antigen occurred 8 months later, there was no further growth of the right adrenal metastasis before he died. From our experience, RTRT with an implanted gold marker might be feasible for the treatment of isolated adrenal metastasis from malignancies including prostate cancer.
- Open Access
- 20 May 2004
- Published by Wiley in International Journal of Cancer
- Vol. 111 (6) , 873-880
Gelsolin gene silencing involving unusual hypersensitivities to dimethylsulfate and KMnO4in vivo footprinting on its promoter region
- 20 May 2004
- Published by Wiley in International Journal of Cancer
- Vol. 111 (6) , 873-880
Open AccessGelsolin gene silencing involving unusual hypersensitivities to dimethylsulfate and KMnO4in vivo footprinting on its promoter region
- 1 September 2002
- Published by Rockefeller University Press
- Vol. 168 (3) , 1182-1187
Adenovirus mediated gelsolin gene therapy for orthotopic human bladder cancer in nude mice.
Gelsolin is an actin regulatory protein that is undetectable or reduced in human bladder tumors compared with normal epithelial cells. Whether the over expression of gelsolin could inhibit tumor growth was investigated in an orthotopic bladder cancer nude mouse model using recombinant adenovirus encoding wild-type gelsolin (Ad-GSN).The 2 human bladder cancer cell lines KU-7 and UMUC-2 were transduced with Ad-GSN in vitro. Flow cytometric analysis was done to examine the cell cycle after transducing the adenovirus. Cell growth was compared with control groups of these cells transduced with adenovirus containing the Escherichia coli beta-galactosidase gene Ad-betagal. In vivo KU-7 cells were introduced into the bladder of nude mice (day 0), followed by 3 injections into the urethra (days 2 to 4) with Ad-GSN or Ad-betagal (1 x 10 pfu). At 8 days after initial adenovirus exposure (day 10) each bladder was sectioned and stained, and the mass of the tumor was digitally determined.Bladder cancer cell growth (KU-7 and UMUC-2) was inhibited after these cells were transduced with Ad-GSN in vitro. Based on flow cytometric analysis over expression of gelsolin may cause these cells to arrest or delay at the G2/M phase of the cell cycle. In the orthotopic bladder cancer model the mass of the tumor was approximately 90% less in Ad-GSN treated animals than in controls.Ad-GSN provides a significant tumor suppressive effect on human bladder cancer cells in this orthotopic nude mouse model. Adenovirus mediated over expression of gelsolin may be useful therapy for human bladder cancer.
- 1 September 2002
- Published by Rockefeller University Press
- Vol. 168 (3) , 1182-1187
Adenovirus mediated gelsolin gene therapy for orthotopic human bladder cancer in nude mice.
Gelsolin is an actin regulatory protein that is undetectable or reduced in human bladder tumors compared with normal epithelial cells. Whether the over expression of gelsolin could inhibit tumor growth was investigated in an orthotopic bladder cancer nude mouse model using recombinant adenovirus encoding wild-type gelsolin (Ad-GSN).The 2 human bladder cancer cell lines KU-7 and UMUC-2 were transduced with Ad-GSN in vitro. Flow cytometric analysis was done to examine the cell cycle after transducing the adenovirus. Cell growth was compared with control groups of these cells transduced with adenovirus containing the Escherichia coli beta-galactosidase gene Ad-betagal. In vivo KU-7 cells were introduced into the bladder of nude mice (day 0), followed by 3 injections into the urethra (days 2 to 4) with Ad-GSN or Ad-betagal (1 x 10 pfu). At 8 days after initial adenovirus exposure (day 10) each bladder was sectioned and stained, and the mass of the tumor was digitally determined.Bladder cancer cell growth (KU-7 and UMUC-2) was inhibited after these cells were transduced with Ad-GSN in vitro. Based on flow cytometric analysis over expression of gelsolin may cause these cells to arrest or delay at the G2/M phase of the cell cycle. In the orthotopic bladder cancer model the mass of the tumor was approximately 90% less in Ad-GSN treated animals than in controls.Ad-GSN provides a significant tumor suppressive effect on human bladder cancer cells in this orthotopic nude mouse model. Adenovirus mediated over expression of gelsolin may be useful therapy for human bladder cancer.
- 1 September 1997
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 158, 908-911
The Significance of RAS Guanine Nucleotide Exchange Factor, Son of Sevenless Protein, in Renal Cell Carcinoma Cell Lines
The aim of the present study is to clarify the significance of the Ras guanine-nucleotide exchange reaction in the proliferation of human renal cell carcinoma cell lines. We examined the expression of human son of sevenless-1 (hSos-1) protein and the epidermal growth factor (EGF) receptor in human renal cell carcinoma cell lines by Western blot analysis. Additionally, a dominant negative H-ras mutant, N116Y, which is known to inhibit the Ras guanine-nucleotide exchange reaction, was transfected into these cell lines by lipofection. Human renal cell carcinoma cell lines expressed much higher amounts of the EGF receptor and hSos-1 protein than normal kidney tissue. Moreover, the N116Y ras mutant could strongly suppress cellular proliferation in these cell lines. Augmentation of the Ras guanine-nucleotide exchange reaction might be essential to the proliferation of human renal cell carcinoma cells.
- 1 September 1997
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 158, 908-911
The Significance of RAS Guanine Nucleotide Exchange Factor, Son of Sevenless Protein, in Renal Cell Carcinoma Cell Lines
The aim of the present study is to clarify the significance of the Ras guanine-nucleotide exchange reaction in the proliferation of human renal cell carcinoma cell lines. We examined the expression of human son of sevenless-1 (hSos-1) protein and the epidermal growth factor (EGF) receptor in human renal cell carcinoma cell lines by Western blot analysis. Additionally, a dominant negative H-ras mutant, N116Y, which is known to inhibit the Ras guanine-nucleotide exchange reaction, was transfected into these cell lines by lipofection. Human renal cell carcinoma cell lines expressed much higher amounts of the EGF receptor and hSos-1 protein than normal kidney tissue. Moreover, the N116Y ras mutant could strongly suppress cellular proliferation in these cell lines. Augmentation of the Ras guanine-nucleotide exchange reaction might be essential to the proliferation of human renal cell carcinoma cells.